Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169658 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
A Phase 2 study of Non-Hodgkin Lymphoma and Marginal Zone Lymphoma, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05169658 is a Phase 2 study of Non-Hodgkin Lymphoma and Marginal Zone Lymphoma that has completed, run by University of Washington. The registered enrollment target is 42 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05169658, a Phase 2 study of Non-Hodgkin Lymphoma and Marginal Zone Lymphoma, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests the effects of mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for the treatment of patients with indolent B-cell non-Hodgkin lymphoma. Mosunetuzumab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79b receptors, and delivers vedotin to kill them. Giving mosunetuzumab with polatuzumab vedotin and obinutuzumab may work better in treating patients with untreated indolent B-cell non-Hodgkin lymphoma.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- BIOLOGICAL Obinutuzumab
- PROCEDURE FDG-Positron Emission Tomography
- BIOLOGICAL Mosunetuzumab
- DRUG Polatuzumab Vedotin
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169658
The ClinicalTrials.gov registry entry for NCT05169658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05169658 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT05169658 about?
NCT05169658 is a clinical study titled "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma". This phase II trial tests the effects of mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for the treatment of patients with indolent B-cell non-Hodgkin lymphoma. Mosunetuzumab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow an...
What is the current status of trial NCT05169658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-03-23. Estimated completion is 2025-04-02.
What conditions does trial NCT05169658 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Grade 3a Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma.
What interventions are being tested in trial NCT05169658?
The interventions under investigation include: Computed Tomography (PROCEDURE), Obinutuzumab (BIOLOGICAL), FDG-Positron Emission Tomography (PROCEDURE), Mosunetuzumab (BIOLOGICAL), Polatuzumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT05169658?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05169658 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.